title: Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis.
abstract: In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.
authors.affiliation: Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università La Sapienza, Roma, Italy. a.spadaro.reuma@virgilio.it
authors.forename: A
authors.initials: A
authors.lastname: Spadaro
authors.forename: A
authors.initials: A
authors.lastname: Scarno
authors.forename: A
authors.initials: A
authors.lastname: Carboni
authors.forename: F M
authors.initials: FM
authors.lastname: Perrotta
authors.forename: C
authors.initials: C
authors.lastname: Catalano
authors.forename: E
authors.initials: E
authors.lastname: Lubrano
authors.forename: G
authors.initials: G
authors.lastname: Valesini
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068582:Certolizumab Pegol; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012074:Remission Induction; D025241:Spondylarthritis / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007166:Immunosuppressive Agents; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol